Cencora, Inc. (NYSE:COR) Shares Purchased by MML Investors Services LLC

MML Investors Services LLC grew its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 87,852 shares of the company's stock after purchasing an additional 2,402 shares during the quarter. MML Investors Services LLC's holdings in Cencora were worth $19,739,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Passumpsic Savings Bank grew its position in shares of Cencora by 4.9% during the third quarter. Passumpsic Savings Bank now owns 6,464 shares of the company's stock worth $1,455,000 after acquiring an additional 304 shares during the last quarter. Virtu Financial LLC grew its position in Cencora by 112.2% during the 3rd quarter. Virtu Financial LLC now owns 10,227 shares of the company's stock worth $2,302,000 after purchasing an additional 5,407 shares during the last quarter. World Investment Advisors LLC purchased a new position in shares of Cencora during the third quarter worth about $4,072,000. Arvest Bank Trust Division acquired a new position in shares of Cencora in the third quarter valued at approximately $218,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Cencora in the 3rd quarter valued at $566,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on COR. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Morgan Stanley set a $288.00 target price on shares of Cencora in a research report on Tuesday, April 15th. Evercore ISI upped their price objective on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Bank of America upped their price objective on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Finally, Wells Fargo & Company raised their price target on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $284.55.

Insider Activity

In other news, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,223 shares of company stock worth $13,580,967 over the last ninety days. Corporate insiders own 10.80% of the company's stock.

Cencora Stock Up 1.3 %

Shares of NYSE:COR traded up $3.66 during midday trading on Friday, hitting $286.05. 1,815,757 shares of the company's stock traded hands, compared to its average volume of 1,520,659. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65. The company has a market cap of $55.47 billion, a PE ratio of 40.69, a P/E/G ratio of 1.31 and a beta of 0.55. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm's fifty day moving average price is $268.09 and its two-hundred day moving average price is $249.16.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.77%. Cencora's payout ratio is currently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.